Utilizing the Cunningham Panel in Clinical Practice

Dr. Craig Shimasaki, President and CEO, Moleculera Labs, reviews the science behind immune-mediated neuropsychiatric disorders and how testing with the Cunningham Panel for antineuronal antibodies can assist in diagnosis and in directing treatment.
Chapters:
2:56 - Start of presentation
4:58 - Neuropsychiatric disorders diagnosed by symptoms, not etiology
7:07 - Can infections cause neuropsychiatric disorders?
8:24 - Rheumatic fever triggered by strep infection
9:42 - Neuronal autoantibodies
10:06 - How does this occur biologically?
13:36 - Study: Brain inflammation on MRI in children with OCD/tics associated with strep infection
17:24 - Other immune-mediated disorders
19:11 - Infections frequently associated with autoimmune encephalopathies
19:57 - Antibodies recognize ‘epitopes’ on infectious agents
22:51 - Molecular mimicry and strep
24:12 - Molecular mimicry and narcolepsy
24:56 - Molecular mimicry, Borrelia burgdorferi (Lyme) and strep
27:23 - How the Cunningham Panel can help diagnose and direct treatment
27:58 - Review of Cunningham Panel assays
30:43 - Case studies of patients tested with the Cunningham Panel
34:39 - Commonalities in patients with antineuronal antibodies
38:03 - Study: Evaluation of the Cunningham Panel
42:52 - Ordering & testing process - Cunningham Panel
44:14 - Guidelines for PANS/PANDAS
49:38 - Free consultation services for healthcare providers

[@deborahd.7281]

Is there any information COVID-19 infection and or vaccines?